Clinical Trial for PB-119 in Subjects With Type 2 Diabetes Mellitus

Summary

This is a randomized, opened, positive drug-controlled (Exenatide, Byetta), sequential parallel group, multiple dose study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of twelve once-weekly subcutaneous doses of PB-119 to subjects with type 2 diabetes mellitus (T2DM).

Timeline

Start

2015-04-08

Primary completion

2016-09-30

Completion

2016-10-27

Drugs

Indications